Proven effective to lower A1C with multiple dosing approaches, including FullSTEP®, a patient-led titration study.3,4
NovoLog® is the #1 selling rapid-acting insulin, and puts improved control in patient hands with FullSTEP®, a manageable, patient-titrated approach.1-3
Delivery devices designed to meet patients’ needs.
For use with NovoLog® FlexPen®, the #1 selling disposable, prefilled insulin device in the world.2 And introducing NovoPen Echo®, the first and only reusable insulin pen with a memory function and half-unit dosing.
NovoLog® is proven effective across a broad range of patients
NovoLog® (insulin aspart [rDNA origin] injection) is approved for pump use in children and adults.
Services for professionals
With a NovoMedLink™ ID you can order product samples, check formulary status and more.
a Managed care plans only. Does not include Medicaid and Medicaid Part D. Intended as a guide. Lower acquisition costs alone do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status is subject to change.
b Formulary data are provided by Fingertip Formulary® and are current as of [February 2013]. Because formularies do change and many health plans offer more than one formulary, please check directly with the health plan to confirm coverage for individual patients. © 2013 Fingertip Formulary. All rights reserved.